Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.

Ryan L Brunsing Dennis H ChenAlexandra SchleinTanya WolfsonAnthony GamstAdrija Mamidipalli Naik Vietti Violi Robert M Marks Bachir A TaouliRohit LoombaYuko KonoClaude B Sirlin

Published in: Radiology. Imaging cancer (2019)

Gadoxetate-enhanced abbreviated MRI is feasible clinically, has a high diagnostic adequacy rate, and, on the basis of our preliminary experience, accurately depicts HCC in high-risk patients. Strategies to enhance follow-up compliance are needed.© RSNA, 2019Keywords: Abdomen/GI, Cirrhosis, Liver, MR-Imaging, Oncology, ScreeningSupplemental material is available for this article.

Keyphrases

contrast enhanced
end stage renal disease
magnetic resonance imaging
ejection fraction
newly diagnosed
chronic kidney disease
public health
palliative care
peritoneal dialysis
prognostic factors
computed tomography
diffusion weighted imaging
patient reported outcomes